The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck’s capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds... Read More

LA JOLLA, Calif. / Oct 04, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

First sites activated with a number of additional rapid-start sites being activated in the coming weeks LA JOLLA, Calif. / Sep 26, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational... Read More

U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation and Rare Pediatric Disease designation for bexicaserin for the treatment of Dravet syndrome LA JOLLA, Calif. / Sep 19, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has... Read More

Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period Favorable safety and tolerability results continue to be observed Data to be presented at the 15 th European Epilepsy Congress in Rome, Italy Full 12-month OLE dataset expected early next year LA JOLLA, Calif. / Sep 08, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq:... Read More

LA JOLLA, Calif. / Sep 06, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to eleven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

LA JOLLA, Calif. / Aug 28, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership team will participate in four upcoming investor conferences. CONFERENCE DETAILS: Event: Wells Fargo Healthcare Conference Details: Hosting investor meetings on... Read More

LA JOLLA, Calif. / Aug 26, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data at the International League Against Epilepsy (ILAE) 15 th Annual European Epilepsy Congress which is taking place in Rome, Italy from September 7-11, 2024. “ILAE is... Read More

LA JOLLA, Calif. / Aug 26, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist... Read More

LA JOLLA, Calif. / Aug 02, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase... Read More

Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) LA JOLLA, Calif. / Jul 29, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... Read More

LA JOLLA, Calif. / Jul 03, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) LA JOLLA, Calif. / Jul 01, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today... Read More

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3% Favorable safety and tolerability results observed 100% of participants who completed the PACIFIC Study entered the OLE End of Phase 2 Meeting scheduled for this summer LA JOLLA, Calif. /... Read More

LA JOLLA, Calif. / Jun 03, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

LA JOLLA, Calif. / May 06, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to seven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data for bexicaserin from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting in April 2024 Bexicaserin global Phase 3 program expected to initiate by YE 2024 LP659 first-in-human Phase 1 single-ascending dose... Read More

PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) LA JOLLA, Calif. / Apr 03, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on... Read More

LA JOLLA, Calif. / Apr 02, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

LA JOLLA, Calif. / Mar 01, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

LA JOLLA, Calif. / Feb 02, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an... Read More

LA JOLLA, Calif. / Feb 01, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February. Conference Details: Event: Guggenheim Healthcare Talks 6th Annual Biotechnology... Read More

LA JOLLA, Calif. / Jan 08, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its voting common stock, including 1,500,000 shares sold pursuant to the exercise in full of the... Read More

LA JOLLA, Calif. / Jan 03, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share. The gross proceeds to Longboard from the... Read More

LA JOLLA, Calif. / Jan 02, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $150 million of shares of its voting common stock. In connection with the... Read More

Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achieved Favorable safety and tolerability results Longboard is rapidly moving forward with preparations for its global Phase 3 program... Read More

• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) LA JOLLA, Calif. / Jan 01, 2024 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a... Read More

Initiated Single-Ascending Dose (SAD) Phase 1 clinical study evaluating LP659 LA JOLLA, Calif. / Nov 29, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is... Read More

Presenting new posters including favorable drug interaction, pharmacokinetic and pharmacodynamic data further highlighting the potential of LP352 to be a best-in-class therapy for a broad range of Developmental and Epileptic Encephalopathies (DEEs) LA JOLLA, Calif. / Nov 21, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel,... Read More

LA JOLLA, Calif. / Nov 03, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Longboard approved the grant of non-qualified stock options to purchase an... Read More

LP352 Phase 1b/2a PACIFIC Study enrollment completed in August 2023 with topline data on track for January 2024 LP659 first-in-human Phase 1 single-ascending dose (SAD) study initiation expected Q4 2023, with topline data expected in the first half 2024 LA JOLLA, Calif. / Nov 02, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel,... Read More

LA JOLLA, Calif. / Nov 01, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will present at three upcoming investor conferences in November. Conference Details: Event: Guggenheim Healthcare Talks 5th Annual Inflammation,... Read More

LA JOLLA, Calif. / Oct 05, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in... Read More

LA JOLLA, Calif. / Sep 19, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in... Read More

LA JOLLA, Calif. / Aug 31, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will participate in three upcoming investor conferences in September. Conference Details: Event: Citi 18th Annual BioPharma Conference Details:... Read More

LA JOLLA, Calif. / Aug 30, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present new and encore data at the 35th International Epilepsy Congress (IEC) and the American College of Clinical Pharmacology (ACCP) Annual Meeting. Presentation Details: IEC... Read More

Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related epilepsies, CDKL5 deficiency disorder, among others PACIFIC topline results remain on track for around year-end 2023 LA JOLLA, Calif. / Aug 23, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a... Read More

LP352 Phase 1b/2a PACIFIC Study enrollment completion expected this summer with topline data expected around year-end 2023 Ended second quarter 2023 with $63.0 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 LA JOLLA, Calif. / Aug 03, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on... Read More

LA JOLLA, Calif. / Aug 03, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will present at the BTIG Virtual Biotechnology Conference and the Wedbush Annual PacGrow Healthcare Conference in New York City. Presentation Details: The... Read More

LA JOLLA, Calif. / Jun 26, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will participate in a fireside chat as part of Cantor Virtual Brain Week on Friday, June 30, 2023, at 11am ET. A webcast of the presentation will be available... Read More

LP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track for second quarter 2023, with Phase 1 topline single-ascending dose data expected in fourth quarter 2023 Ended first quarter 2023 with $76.1 million in cash, cash equivalents and investments; cash runway is... Read More

LA JOLLA, Calif. / Apr 11, 2023 / Business Wire / Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 4:30pm ET. To access a webcast... Read More

SAN DIEGO and GAINESVILLE, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Longboard Pharmaceuticals, Inc. (NASD: LBPH) to provide CDMO services. The agreement spans a range of Societal CDMO’s offerings including technology transfer and analytical method validation activities... Read More

LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 LP659 Phase 1 initiation of first in-human clinical study on track for first half of 2023, with Phase 1 topline single-ascending dose (SAD) data expected in the second half of 2023 Ended 2022 with $67.6 million in cash, cash equivalents and investments; cash runway is... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:30pm ET (1:30pm PT) on the same day. CONFERENCE CALL DETAILS: Live Call Participation: To join the... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its voting common stock, including the exercise in full by the underwriters of their option to purchase an additional 750,000 shares, at a price to... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its voting common stock at a price to the public of $4.00 per share. The gross proceeds to Longboard from the offering, before deducting... Read More

Longboard Pharmaceuticals, Inc . (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $20 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the... Read More

LP352 exhibited a strong correlation between plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) concentration, which increased in a dose-dependent and consistent manner LP352 demonstrated early quantitative electroencephalogram (qEEG) changes, and sustained effects on qEEG activity after continuous dosing in a dose-dependent manner indicating receptor engagement Favorable safety and tolerability results were observed... Read More

Presenting data evaluating LP352 engagement of central 5-HT2C receptors via effects on prolactin, and assessing binding activity and functional agonism of LP352 at the 5-HT2 receptors Hosting scientific exhibit highlighting the ongoing Phase 1b/2a PACIFIC Study, and LP352, a novel, highly selective 5-HT2C superagonist in development for rare seizure disorders Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day, which is taking place November 14-15, 2022, in New York City. Presentation... Read More

LP352 Phase 1b/2a PACIFIC Study in participants with a range of developmental and epileptic encephalopathies (DEEs) ages 12-65 on track for topline data in second half 2023 Phase 1 open-label study to assess central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352 in healthy volunteers; data on track for fourth quarter 2022 Pre-investigational new drug (IND) meeting with the FDA to finalize... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & CEO, will participate in a panel discussion at the Cantor Neurology & Psychiatry Conference, which is taking place October 6-7, 2022, in San Francisco, CA. Presentation Details: Panel Title: Next... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the Citi Annual BioPharma Conference, which is taking place September 7-8, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright Global Investment... Read More

LP352 Phase 1b/2a PACIFIC Study remains on track for completion in the second half of 2023; recently expanded the participant age range to 12-65 years old and added open-label extension study Initiated a Phase 1 open-label study to assess central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352 in healthy volunteers; data expected around year-end 2022 IND submission for LP659 remains on track for... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present as a panelist at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35PM ET. Presentation Details: Panel Title: Got My Mind Set On You -... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & CEO, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 3:00PM ET, in New York City. To access a webcast of the presentation, please visit the “ Events & Presentations ”... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership team will participate in five upcoming events being hosted by respected epilepsy-focused patient advocacy groups. "We are pleased to be included in these key epilepsy conferences this summer. The opportunity... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the Citi Movement Disorder & Epilepsy Co-Panel, on May 18, 2022, and present virtually in a fireside chat format at the H.C. Wainwright Global Investment Hybrid Conference,... Read More

Phase 1 data for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies, presented at the American Academy of Neurology (AAN) Annual Meeting Initiated Phase 1b/2a PACIFIC Study evaluating LP352 for participants with developmental and epileptic encephalopathies (DEEs) LP659 IND submission remains on track for fourth quarter 2022 Cash position expected to support operations into 2024... Read More

Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that single ascending dose and multiple ascending dose data from the Phase 1 study evaluating LP352 in healthy volunteers will be presented at the American... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate virtually in the Rare and General Epilepsy and Seizure Disorders panel during Cantor Fitzgerald’s Rare Orphan Disease Summit, taking place March 29–30, 2022. Panel Details: Title:... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & Chief Executive Officer, will present at the Maxim Group LLC Virtual Growth Conference, taking place March 28–30, 2022. The presentation will be available to registered users via M-Vest, a division... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical... Read More

Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs) LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndrome LP659 IND submission remains on track for second half of 2022 Cash position expected to support operations into 2024 based on current business plan... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at the H.C. Wainwright BioConnect Virtual Conference. The presentation webcast will be available beginning Monday, January 10, 2022, at 7:00 AM ET. To access a webcast of the... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors. "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the following conferences: Guggenheim Healthcare Talks Neuro/Immunology Virtual Conference: Hosting investor meetings Monday, November 15 – Tuesday, November 16, 2021 Evercore... Read More

Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies Initiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants with developmental and epileptic encephalopathies (DEEs) in Q1 2022 IND-enabling preclinical studies for LP143 and LP659 ongoing Continuing to... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced Steven W. Spector, J.D., has joined the company as its General Counsel. "We are thrilled to have Steven formally join Longboard at this time. Steven brings tremendous operational and transactional expertise through all stages of drug... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Cantor Virtual Global Healthcare Conference on September 28, 2021. Presentation Details: Cantor Global Healthcare Conference: Tuesday, September 28,... Read More

Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin Company plans to initiate a Phase 1b/2a clinical trial in adult participants with developmental and epileptic encephalopathies (DEEs) in Q1 2022 Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company... Read More

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin R. Lind, Longboard’s President & Chief Executive Officer, will present virtually in a fireside chat format at two upcoming investor conferences: Citi’s 16th Annual BioPharma Virtual Conference and H.C. Wainwright’s 23rd Annual... Read More

Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial for LP352, a potential treatment for severe epileptic indications, with topline results expected in 2021 Initiated a number of IND-enabling preclinical studies for LP143 and LP659 Established corporate office in one of the largest life sciences hubs, San Diego, California, while continuing to expand capabilities internationally as... Read More

Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 Successfully completed an upsized initial public offering (IPO) raising approximately $84.8 million in total gross proceeds (before deducting underwriter and issuance costs) Strengthened leadership team with the addition of team members... Read More